Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion

Objective To evaluate the significance of the JAK-STAT pathway in insulin-induced cardioprotection from reperfusion injury. Methods In isolated perfused rat hearts subjected to insulin therapy (0.3 mU/ml) ± AG490 (5 µM, JAK-STAT inhibitor), the phosphorylation state of STAT3 and Akt was determined a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Basic research in cardiology 2008-09, Vol.103 (5), p.444-453
Hauptverfasser: Fuglesteg, Britt N., Suleman, Naushaad, Tiron, Crina, Kanhema, Tambuzai, Lacerda, Lydia, Andreasen, Thomas V., Sack, Michael N., Jonassen, Anne K., Mjøs, Ole D., Opie, Lionel H., Lecour, Sandrine
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 453
container_issue 5
container_start_page 444
container_title Basic research in cardiology
container_volume 103
creator Fuglesteg, Britt N.
Suleman, Naushaad
Tiron, Crina
Kanhema, Tambuzai
Lacerda, Lydia
Andreasen, Thomas V.
Sack, Michael N.
Jonassen, Anne K.
Mjøs, Ole D.
Opie, Lionel H.
Lecour, Sandrine
description Objective To evaluate the significance of the JAK-STAT pathway in insulin-induced cardioprotection from reperfusion injury. Methods In isolated perfused rat hearts subjected to insulin therapy (0.3 mU/ml) ± AG490 (5 µM, JAK-STAT inhibitor), the phosphorylation state of STAT3 and Akt was determined after 15 min of reperfusion. Infarct size was measured after 120 min of reperfusion. Isolated cardiac myocytes from wild type (WT) and cardiac specific STAT3 deficient mice were treated with insulin at reoxygenation following simulated ischemia (SI, 26 h). Cell viability was measured after 120 min of reoxygenation following SI, whereas phosphorylation state of Akt was measured after 15 min of reoxygenation following SI. Results Insulin given at reperfusion led to phosphorylation of STAT3 and Akt both of which were inhibited by AG490. AG490 also blocked the insulin-dependent decrease in infarct size, supporting a role for JAK-STAT in cardioprotection. In addition, insulin protection from SI was blocked in myocytes from the STAT3 deficient mice, or in WT mice treated with AG490. Furthermore, insulin failed to phosphorylate Akt in the STAT3 deficient cardiomyocytes. Conclusion Insulin-induced cardioprotection at reperfusion occurs through activation of STAT3. Inhibiting STAT3 by AG490, or STAT3 depletion in cardiac myocytes affects activation of Akt, suggesting close interaction between STAT3 and Akt in the cardioprotective signalling pathway activated by insulin treatment at reperfusion.
doi_str_mv 10.1007/s00395-008-0728-x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3398508</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69448165</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-6f853b2e9254d36dfd6f6da620a8fabb794850966e8e6f360aaff4218f6a83533</originalsourceid><addsrcrecordid>eNqFksFu1DAURS0EotPCB7BBFgt2oc9x4jgbJFRBQarUBbC2XhJ7xlXGDrYzdD6E_8XTDJQiIVa2dM-9z8-6hLxg8IYBNOcRgLd1ASALaEpZ3D4iK1bxumAS-GOyAg5QyKqUJ-Q0xhsAVgnBnpITJmuAStYr8uOzXTscaQro4jD3OlB0A8U-2R0mH6g3i9YHOyXrHeXURmrdzo87PeQLTRtNewyD9VPwSR-cmsa72NG6NZ0wbb7j_ldmNnX77IvzuJgDTllMNOhJBzPHPOQZeWJwjPr58TwjXz-8_3Lxsbi6vvx08e6q6KtWpkIYWfOu1G1ZVwMXgxmEEQOKElAa7LqmzTtCK4SWWhguANGYqmTSCJS85vyMvF1yp7nb6qHXLu86qinYLYa98mjVQ8XZjVr7neK8zckyB7w-BgT_bdYxqa2NvR5HdNrPUYm2qiQT9X9B1jas4ZJl8NVf4I2fQ_7LqErGoWZclBliC9QHH2PQ5veTGahDNdRSDZWroQ7VULfZ8_LPXe8dxy5koFyAmCW31uF-8r9TfwIqlMml</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213051362</pqid></control><display><type>article</type><title>Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Fuglesteg, Britt N. ; Suleman, Naushaad ; Tiron, Crina ; Kanhema, Tambuzai ; Lacerda, Lydia ; Andreasen, Thomas V. ; Sack, Michael N. ; Jonassen, Anne K. ; Mjøs, Ole D. ; Opie, Lionel H. ; Lecour, Sandrine</creator><creatorcontrib>Fuglesteg, Britt N. ; Suleman, Naushaad ; Tiron, Crina ; Kanhema, Tambuzai ; Lacerda, Lydia ; Andreasen, Thomas V. ; Sack, Michael N. ; Jonassen, Anne K. ; Mjøs, Ole D. ; Opie, Lionel H. ; Lecour, Sandrine</creatorcontrib><description>Objective To evaluate the significance of the JAK-STAT pathway in insulin-induced cardioprotection from reperfusion injury. Methods In isolated perfused rat hearts subjected to insulin therapy (0.3 mU/ml) ± AG490 (5 µM, JAK-STAT inhibitor), the phosphorylation state of STAT3 and Akt was determined after 15 min of reperfusion. Infarct size was measured after 120 min of reperfusion. Isolated cardiac myocytes from wild type (WT) and cardiac specific STAT3 deficient mice were treated with insulin at reoxygenation following simulated ischemia (SI, 26 h). Cell viability was measured after 120 min of reoxygenation following SI, whereas phosphorylation state of Akt was measured after 15 min of reoxygenation following SI. Results Insulin given at reperfusion led to phosphorylation of STAT3 and Akt both of which were inhibited by AG490. AG490 also blocked the insulin-dependent decrease in infarct size, supporting a role for JAK-STAT in cardioprotection. In addition, insulin protection from SI was blocked in myocytes from the STAT3 deficient mice, or in WT mice treated with AG490. Furthermore, insulin failed to phosphorylate Akt in the STAT3 deficient cardiomyocytes. Conclusion Insulin-induced cardioprotection at reperfusion occurs through activation of STAT3. Inhibiting STAT3 by AG490, or STAT3 depletion in cardiac myocytes affects activation of Akt, suggesting close interaction between STAT3 and Akt in the cardioprotective signalling pathway activated by insulin treatment at reperfusion.</description><identifier>ISSN: 0300-8428</identifier><identifier>EISSN: 1435-1803</identifier><identifier>DOI: 10.1007/s00395-008-0728-x</identifier><identifier>PMID: 18500485</identifier><language>eng</language><publisher>Dordrecht: D. Steinkopff-Verlag</publisher><subject>Animals ; Cardiology ; Cardiotonic Agents - pharmacology ; Cell Death - drug effects ; Cell Survival - drug effects ; Disease Models, Animal ; Enzyme Inhibitors - pharmacology ; Insulin - pharmacology ; Male ; Medicine ; Medicine &amp; Public Health ; Mice ; Mice, Mutant Strains ; Myocardial Reperfusion Injury - drug therapy ; Myocardial Reperfusion Injury - metabolism ; Myocardial Reperfusion Injury - pathology ; Myocytes, Cardiac - cytology ; Myocytes, Cardiac - metabolism ; Original Contribution ; Oxygen - pharmacology ; Phosphorylation ; Proto-Oncogene Proteins c-akt - metabolism ; Rats ; Rats, Wistar ; Signal Transduction - physiology ; STAT3 Transcription Factor - antagonists &amp; inhibitors ; STAT3 Transcription Factor - genetics ; STAT3 Transcription Factor - metabolism ; Tyrphostins - pharmacology</subject><ispartof>Basic research in cardiology, 2008-09, Vol.103 (5), p.444-453</ispartof><rights>Springer 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-6f853b2e9254d36dfd6f6da620a8fabb794850966e8e6f360aaff4218f6a83533</citedby><cites>FETCH-LOGICAL-c498t-6f853b2e9254d36dfd6f6da620a8fabb794850966e8e6f360aaff4218f6a83533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00395-008-0728-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00395-008-0728-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18500485$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fuglesteg, Britt N.</creatorcontrib><creatorcontrib>Suleman, Naushaad</creatorcontrib><creatorcontrib>Tiron, Crina</creatorcontrib><creatorcontrib>Kanhema, Tambuzai</creatorcontrib><creatorcontrib>Lacerda, Lydia</creatorcontrib><creatorcontrib>Andreasen, Thomas V.</creatorcontrib><creatorcontrib>Sack, Michael N.</creatorcontrib><creatorcontrib>Jonassen, Anne K.</creatorcontrib><creatorcontrib>Mjøs, Ole D.</creatorcontrib><creatorcontrib>Opie, Lionel H.</creatorcontrib><creatorcontrib>Lecour, Sandrine</creatorcontrib><title>Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion</title><title>Basic research in cardiology</title><addtitle>Basic Res Cardiol</addtitle><addtitle>Basic Res Cardiol</addtitle><description>Objective To evaluate the significance of the JAK-STAT pathway in insulin-induced cardioprotection from reperfusion injury. Methods In isolated perfused rat hearts subjected to insulin therapy (0.3 mU/ml) ± AG490 (5 µM, JAK-STAT inhibitor), the phosphorylation state of STAT3 and Akt was determined after 15 min of reperfusion. Infarct size was measured after 120 min of reperfusion. Isolated cardiac myocytes from wild type (WT) and cardiac specific STAT3 deficient mice were treated with insulin at reoxygenation following simulated ischemia (SI, 26 h). Cell viability was measured after 120 min of reoxygenation following SI, whereas phosphorylation state of Akt was measured after 15 min of reoxygenation following SI. Results Insulin given at reperfusion led to phosphorylation of STAT3 and Akt both of which were inhibited by AG490. AG490 also blocked the insulin-dependent decrease in infarct size, supporting a role for JAK-STAT in cardioprotection. In addition, insulin protection from SI was blocked in myocytes from the STAT3 deficient mice, or in WT mice treated with AG490. Furthermore, insulin failed to phosphorylate Akt in the STAT3 deficient cardiomyocytes. Conclusion Insulin-induced cardioprotection at reperfusion occurs through activation of STAT3. Inhibiting STAT3 by AG490, or STAT3 depletion in cardiac myocytes affects activation of Akt, suggesting close interaction between STAT3 and Akt in the cardioprotective signalling pathway activated by insulin treatment at reperfusion.</description><subject>Animals</subject><subject>Cardiology</subject><subject>Cardiotonic Agents - pharmacology</subject><subject>Cell Death - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Disease Models, Animal</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Insulin - pharmacology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mice</subject><subject>Mice, Mutant Strains</subject><subject>Myocardial Reperfusion Injury - drug therapy</subject><subject>Myocardial Reperfusion Injury - metabolism</subject><subject>Myocardial Reperfusion Injury - pathology</subject><subject>Myocytes, Cardiac - cytology</subject><subject>Myocytes, Cardiac - metabolism</subject><subject>Original Contribution</subject><subject>Oxygen - pharmacology</subject><subject>Phosphorylation</subject><subject>Proto-Oncogene Proteins c-akt - metabolism</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Signal Transduction - physiology</subject><subject>STAT3 Transcription Factor - antagonists &amp; inhibitors</subject><subject>STAT3 Transcription Factor - genetics</subject><subject>STAT3 Transcription Factor - metabolism</subject><subject>Tyrphostins - pharmacology</subject><issn>0300-8428</issn><issn>1435-1803</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFksFu1DAURS0EotPCB7BBFgt2oc9x4jgbJFRBQarUBbC2XhJ7xlXGDrYzdD6E_8XTDJQiIVa2dM-9z8-6hLxg8IYBNOcRgLd1ASALaEpZ3D4iK1bxumAS-GOyAg5QyKqUJ-Q0xhsAVgnBnpITJmuAStYr8uOzXTscaQro4jD3OlB0A8U-2R0mH6g3i9YHOyXrHeXURmrdzo87PeQLTRtNewyD9VPwSR-cmsa72NG6NZ0wbb7j_ldmNnX77IvzuJgDTllMNOhJBzPHPOQZeWJwjPr58TwjXz-8_3Lxsbi6vvx08e6q6KtWpkIYWfOu1G1ZVwMXgxmEEQOKElAa7LqmzTtCK4SWWhguANGYqmTSCJS85vyMvF1yp7nb6qHXLu86qinYLYa98mjVQ8XZjVr7neK8zckyB7w-BgT_bdYxqa2NvR5HdNrPUYm2qiQT9X9B1jas4ZJl8NVf4I2fQ_7LqErGoWZclBliC9QHH2PQ5veTGahDNdRSDZWroQ7VULfZ8_LPXe8dxy5koFyAmCW31uF-8r9TfwIqlMml</recordid><startdate>20080901</startdate><enddate>20080901</enddate><creator>Fuglesteg, Britt N.</creator><creator>Suleman, Naushaad</creator><creator>Tiron, Crina</creator><creator>Kanhema, Tambuzai</creator><creator>Lacerda, Lydia</creator><creator>Andreasen, Thomas V.</creator><creator>Sack, Michael N.</creator><creator>Jonassen, Anne K.</creator><creator>Mjøs, Ole D.</creator><creator>Opie, Lionel H.</creator><creator>Lecour, Sandrine</creator><general>D. Steinkopff-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7TM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20080901</creationdate><title>Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion</title><author>Fuglesteg, Britt N. ; Suleman, Naushaad ; Tiron, Crina ; Kanhema, Tambuzai ; Lacerda, Lydia ; Andreasen, Thomas V. ; Sack, Michael N. ; Jonassen, Anne K. ; Mjøs, Ole D. ; Opie, Lionel H. ; Lecour, Sandrine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-6f853b2e9254d36dfd6f6da620a8fabb794850966e8e6f360aaff4218f6a83533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Cardiology</topic><topic>Cardiotonic Agents - pharmacology</topic><topic>Cell Death - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Disease Models, Animal</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Insulin - pharmacology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mice</topic><topic>Mice, Mutant Strains</topic><topic>Myocardial Reperfusion Injury - drug therapy</topic><topic>Myocardial Reperfusion Injury - metabolism</topic><topic>Myocardial Reperfusion Injury - pathology</topic><topic>Myocytes, Cardiac - cytology</topic><topic>Myocytes, Cardiac - metabolism</topic><topic>Original Contribution</topic><topic>Oxygen - pharmacology</topic><topic>Phosphorylation</topic><topic>Proto-Oncogene Proteins c-akt - metabolism</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Signal Transduction - physiology</topic><topic>STAT3 Transcription Factor - antagonists &amp; inhibitors</topic><topic>STAT3 Transcription Factor - genetics</topic><topic>STAT3 Transcription Factor - metabolism</topic><topic>Tyrphostins - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fuglesteg, Britt N.</creatorcontrib><creatorcontrib>Suleman, Naushaad</creatorcontrib><creatorcontrib>Tiron, Crina</creatorcontrib><creatorcontrib>Kanhema, Tambuzai</creatorcontrib><creatorcontrib>Lacerda, Lydia</creatorcontrib><creatorcontrib>Andreasen, Thomas V.</creatorcontrib><creatorcontrib>Sack, Michael N.</creatorcontrib><creatorcontrib>Jonassen, Anne K.</creatorcontrib><creatorcontrib>Mjøs, Ole D.</creatorcontrib><creatorcontrib>Opie, Lionel H.</creatorcontrib><creatorcontrib>Lecour, Sandrine</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Nucleic Acids Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Basic research in cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fuglesteg, Britt N.</au><au>Suleman, Naushaad</au><au>Tiron, Crina</au><au>Kanhema, Tambuzai</au><au>Lacerda, Lydia</au><au>Andreasen, Thomas V.</au><au>Sack, Michael N.</au><au>Jonassen, Anne K.</au><au>Mjøs, Ole D.</au><au>Opie, Lionel H.</au><au>Lecour, Sandrine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion</atitle><jtitle>Basic research in cardiology</jtitle><stitle>Basic Res Cardiol</stitle><addtitle>Basic Res Cardiol</addtitle><date>2008-09-01</date><risdate>2008</risdate><volume>103</volume><issue>5</issue><spage>444</spage><epage>453</epage><pages>444-453</pages><issn>0300-8428</issn><eissn>1435-1803</eissn><abstract>Objective To evaluate the significance of the JAK-STAT pathway in insulin-induced cardioprotection from reperfusion injury. Methods In isolated perfused rat hearts subjected to insulin therapy (0.3 mU/ml) ± AG490 (5 µM, JAK-STAT inhibitor), the phosphorylation state of STAT3 and Akt was determined after 15 min of reperfusion. Infarct size was measured after 120 min of reperfusion. Isolated cardiac myocytes from wild type (WT) and cardiac specific STAT3 deficient mice were treated with insulin at reoxygenation following simulated ischemia (SI, 26 h). Cell viability was measured after 120 min of reoxygenation following SI, whereas phosphorylation state of Akt was measured after 15 min of reoxygenation following SI. Results Insulin given at reperfusion led to phosphorylation of STAT3 and Akt both of which were inhibited by AG490. AG490 also blocked the insulin-dependent decrease in infarct size, supporting a role for JAK-STAT in cardioprotection. In addition, insulin protection from SI was blocked in myocytes from the STAT3 deficient mice, or in WT mice treated with AG490. Furthermore, insulin failed to phosphorylate Akt in the STAT3 deficient cardiomyocytes. Conclusion Insulin-induced cardioprotection at reperfusion occurs through activation of STAT3. Inhibiting STAT3 by AG490, or STAT3 depletion in cardiac myocytes affects activation of Akt, suggesting close interaction between STAT3 and Akt in the cardioprotective signalling pathway activated by insulin treatment at reperfusion.</abstract><cop>Dordrecht</cop><pub>D. Steinkopff-Verlag</pub><pmid>18500485</pmid><doi>10.1007/s00395-008-0728-x</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0300-8428
ispartof Basic research in cardiology, 2008-09, Vol.103 (5), p.444-453
issn 0300-8428
1435-1803
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3398508
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Animals
Cardiology
Cardiotonic Agents - pharmacology
Cell Death - drug effects
Cell Survival - drug effects
Disease Models, Animal
Enzyme Inhibitors - pharmacology
Insulin - pharmacology
Male
Medicine
Medicine & Public Health
Mice
Mice, Mutant Strains
Myocardial Reperfusion Injury - drug therapy
Myocardial Reperfusion Injury - metabolism
Myocardial Reperfusion Injury - pathology
Myocytes, Cardiac - cytology
Myocytes, Cardiac - metabolism
Original Contribution
Oxygen - pharmacology
Phosphorylation
Proto-Oncogene Proteins c-akt - metabolism
Rats
Rats, Wistar
Signal Transduction - physiology
STAT3 Transcription Factor - antagonists & inhibitors
STAT3 Transcription Factor - genetics
STAT3 Transcription Factor - metabolism
Tyrphostins - pharmacology
title Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A48%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Signal%20transducer%20and%20activator%20of%20transcription%203%20is%20involved%20in%20the%20cardioprotective%20signalling%20pathway%20activated%20by%20insulin%20therapy%20at%20reperfusion&rft.jtitle=Basic%20research%20in%20cardiology&rft.au=Fuglesteg,%20Britt%20N.&rft.date=2008-09-01&rft.volume=103&rft.issue=5&rft.spage=444&rft.epage=453&rft.pages=444-453&rft.issn=0300-8428&rft.eissn=1435-1803&rft_id=info:doi/10.1007/s00395-008-0728-x&rft_dat=%3Cproquest_pubme%3E69448165%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213051362&rft_id=info:pmid/18500485&rfr_iscdi=true